Vacunas Sanofi Pasteur MSD
Referencias
  1. Global Alliance for Vaccines and Immunization (GAVI). Fact sheet N°169. Revised March 2001. 4 pages.
  2. Mc Lean AR. Vaccines and their impact on the control of disease. Brit Med Bull 1998; 54(3):545-56.
  3. WHO. WHO fact sheet on smallpox. Oct. 2001. Available from: URL: http://www.who.int/emc/diseases/smallpox/factsheet.html (viewed on 20/09/2000).
  4. Certification of poliomyelitis eradication, European region, june 2002. Weekly Epidemiological Record. WHO 2002; 27(77): 221-8.
  5. Vitek CR and Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis 1998;4(4):539-50.
  6. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 2000;181(1):S2-S9.
  7. Beytout J, Denis F et Allaert FA. Description of vaccination status of the adult population in France. Med Mal Infect 2002;32(12):678-688.
  8. Reef SE, Frey TK, Theall K et al. The changing epidemiology of rubella in the 1990s. On the verge of elimination and new challenges for control and prevention. JAMA 2002;287(4):464-72.
  9. Peltola HK, Davidkin I, Paunio M et al. Mumps and Rubella eliminated from Finland. JAMA 2000.284(20):2643-7.
  10. Lovoll O, Sandbu S. Measles and measles immunisation in Norway: Historical review and present situation. Eurosurveillance Wkly 2002;Vol 6 (12):3-5. Available from: URL: http://www.eurosurveillance.org/ew/2002/020321.asp#2 (viewed on 20/04/06).
  11. Bonmarin I et Levy-Bruhl D. Measles in France: the epidemiological impact of uboptimal immunisation coverage. Eurosurveillance 2002;7(4):1-4.
  12. Rotily M, Guagliardo V, Fontaine D et al. Evaluation of measles-mumps-rubella vaccine coverage in three year olds in twelve French regions. Temporal evolution and associated factors. Rev Epidemiol Santé Publique 2001;49:331-41.
  13. Siedler A, Rasch G. Measles outbreak in Germany. Eurosurveillance Wkly 2002;12:1-3. Available from: URL: http://www.eurosurv.org/2002/020321.html (viewed on 17/06/2002).
  14. Hanratty B et al. UK measles outbreak in non-immune anthroposophic communities: the implications for the elimination of measles from Europe. Epidemiol Infect 2000;125(2):377-83.
  15. Ciofi degli Atti M, Salmaso S. Measles increase in Italy. BEN Notiziario ISS 2002;15(4):1-3. Available from: URL: http://www.ben.iss.it/pre_2002/aprile02/2eng.htm (viewed on 20/04/06).
  16. Immunisation against infectious disease 1996. Eds Salisbury DM and Begg NT.
  17. Floret D. Death by community bacterial infection. Arch Paediatr 2001;8(4): 705-11. WHO. Hepatitis B. Fact sheet
  18. WHO/204. Revised October 2000. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html (viewed on 20/04/06).
  19. Mele A, Stroffolini T, and Zanetti AR. Hepatitis B in Italy: Where we are ten years after the introduction of mass vaccination. J Med Virol 2002;67(3):440-3.
  20. Pr Abenhaim. The influenza status. Minutes from the debate held at the Palais du Luxembourg (seat of the French Senate) in Paris, 20th November 2001.
  21. CDC. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 2002;51 (RR-3):1-31.
  22. Peltola H et al. Perspective: A five country analysis of the impact of four different Hæmophilus influenzæ type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999;179:223-9.
  23. Ramet J et al. Confederation of the European Specialists of Paediatrics (CESP)/European Academy of Paediatrics (EAP) CESP/EAP. Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract. 2005 Nov;59(11):1248-50.
  24. Banz K et al. The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ. 2004 Feb;5(1):46-53.
  25. Atkinson et al. in Epidemiology and Prevention of vaccine-preventable diseases, 8th edition, January 2004.
  26. Seward JF et al. "Varicella disease after introduction of varicella vaccine in the United States, 1995-2000." Journal of the American Medical Association 287, no. 5 (2002): 606-611.
  27. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005 Feb 3;352(5):450-8.
  28. Stiko recommendation for Varicella Vaccination. Epidemiologisches Bulletin, Nr 30. 23 July 2004.
  29. http://www.keel.org.gr/en/.
  30. Ramet J et al. Confederation of the European Specialists of Paediatrics (CESP)/European Academy of Paediatrics (EAP) CESP/EAP. Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract. 2005 Nov;59(11):1248-50.
  31. Spanish Ministry of Health recommendation for varicella vaccination : http://www.msc.es/fr/ciudadanos/proteccionSalud/infancia/docs/VARICELATriptico.pdf (viewed on 20.04.06).
  32. Varicella vaccination in Switzerland. Bulletin officiel de l’Office fédéral de la santé publique: OFSP Bulletin n°45:846-848.
  33. Austrian Ministry of Health recommendation for varicella vaccination : http://www.bmgf.gv.at/cms/site/attachments/1/4/0/CH0016/CMS1038913010412/impf plan_2006.pdf (viewed on 20.04.06).
  34. Plotkin SL and Plotkin SA. A short history of vaccination. Chapter one. In: Plotkin and Orenstein. Vaccines, 3rd edition. Philadelphia (PA): WB Saunders, 1999. Page 1.
  35. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15(3):369-90.
  36. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002;20:2562-78.
  37. CDC. Impact of vaccines universally recommended for children - United States, 1900-1998. MMWR 1999;48,(12):243-8.
  38. Skjeldestad FE et al. Prophylactic Quadrivalent Human Papillomavirus (HPV) (types 6, 11, 16, and 18) L1 virus-like particle (VLP) Vaccine(Gardasil™) reduces Cervical Intraepithelial Neoplasia (CIN)2/ 3 risk Abstract presented et Infectious Diseases Society of America(IDSA), October 6-9 2005, San Francisco,US.
  39. Ferlay J, Bray F, Pisani P et al, editors. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. version 2.0. IARC Press, Lyon 2004.
  40. Como la referencia 39
  41. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
  42. Koutsky LA. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-6.
  43. Koutsky LA et al. Epidemiology of genital human papillomavirus infection. Epidemiology Rev 1988;10 :122-63.
  44. Syrjänen K et al.Prevalence, Incidence,and estimated life-time risk of cervical cancer Papillomavirus infections in a non selected Finnish female population.Sex Transm Dis 1990; 17:15-19.
  45. Koutsky LA. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-6.
  46. Koutsky LA et al. Epidemiology of genital human papillomavirus infection. Epidemiology Rev 1988;10 :122-63.
  47. Syrjänen K et al.Prevalence, Incidence,and estimated life-time risk of cervical cancer Papillomavirus infections in a non selected Finnish female population.Sex Transm Dis 1990; 17:15-19.
  48. Sawaya GF, McConnell KJ, Kulasingam SL et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349:1501-1509.
  49. Clifford GM, Smith JS, Aguado T et al.Comparison of HPV type distribution in high- grade cervical lesions and cervical cancer: a meta- analysis. Br J Cancer 2003;89:101-105.
  50. Sotlar K, Diemer D, Dethleffs A et al.Detection and typing of Human Papillomavirus by E6 Nested Multiplex PCR. Journal of Clinical Microbiology 2004;3176-3184.
  51. Liaw K-L, Glass AG, Manos MM et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-960.
  52. Voglino G, Poso F, Privitera S et al. The role of human papillomavirus in cyto-histological practice: Distribution and prevalence of high-risk strains (16, 18, 31, 33, and 35) in intraepithelial lesions and neoplasia of the uterine cervix. Pathologica 2000;92:512-523.
  53. Munoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
  54. Clifford GM, Rana RK et al.Human Papillomavirus genotype distribution in Low-grade cervical lesions:Comparison by geographic region and with cervical cancer.Cancer Epidemiol,Biomarkers &Prev. 2005;14: 1157-1163.
  55. von Krogh G. Management of anogenital warts(condylomata acuminate).Eur J Dermatol 2001;11:598-603.
  56. Wieland U, Pfister H. papillomaviruses in human pathology: Epidemiology, pathogenesis and oncologic role.In:Gross,Barasso EDS.Human Papillomavirus Infection:A clinical atlas.Ullstein Mosby;1997.p1-18.
  57. Crombie IK, Orbell S, Johnston G et al. Women's experiences at cervical screening. Scott Med. 1995; 40:81-82.
  58. French DP, Maissi E and Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer 2004; 91:1887-1892.
  59. van Wijngaarden WJ, Duncan ID and Hussain KA. Screening for cervical neoplasia in Dundee and Angus: 10 years on. Br J Obstet Gynaecol 1995;102 :137-142.
  60. Skjeldestad FE et al. Prophylactic Quadrivalent Human Papillomavirus (HPV) (types 6, 11, 16, and 18) L1 virus-like particle (VLP) Vaccine(Gardasil™) reduces Cervical Intraepithelial Neoplasia (CIN)2/ 3 risk Abstract presented et Infectious Diseases Society of America(IDSA), October 6-9 2005, San Francisco,US.
  61. Gnann JW et al. Herpes Zoster. N Engl J Med 2002;347(5):340-6.
  62. Katz et al. Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life. Clin Infec Diseases 2004; 39:342-8.
  63. Johnson R W. Consequences and Management of Pain in Herpes Zoster. The Journal of Infectious Diseases. 2002;186(Suppl 1):S83-90.
  64. Edmunds WJ et al. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
  65. Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22):2271-84.
  66. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32:1481-6.
  67. Edmunds WJ et al. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
  68. Gnann JW et al. Herpes Zoster. N Engl J Med 2002;347(5):340-6.
  69. Edmunds WJ et al. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
  70. Thomas SL et al. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004:4;26-33.
  71. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Practice 1975:25:571-5.
  72. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Practice 1975: 25: 571-5. and "Population statistics" Eurostat, European Commission, 2004 edition).
  73. World Population Ageing 1950-2050. Population Division, DESA, United Nations.
  74. Katz J et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342-8.
  75. Gnann JW et al. Herpes Zoster. N Engl J Med 2002;347(5):340-6.
  76. Volpi A. et al., Current Management of Herpes Zoster, The European View. Am J Clin Dermatol 2005: 6(5):317-325.
  77. Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84.
  78. Rotavirus. Centers for Disease Control and Prevention: Respiratory and Enteric Viruses Brand. www.cdc.gov/ncidod/dvrd/revb/gastro/rotavirus.htm.
  79. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases. 2003;9:565-572.
  80. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S7-S11.
  81. Vesikari T et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006 Jan 5;354(1):23-33.
  82. Clark HF et al. Rotavirus Vaccines. In: Plotkin SA, Orenstein WA eds. Vaccines 4th Ed. Philadelphia: Saunders; 2004. p. 1327-1345.
  83. Velazquez FR et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335(14):1022-1028.
  84. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279-1295.
  85. King CK et al. Managing acute gastroenteritis among child. CDC MMWR 2003;52(RR16):1-16.
  86. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279-1295.
  87. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279-1295.
  88. Matson D.O. In: Long SS Ed. Principles and Practice of Paediatric Infectious Diseases. New York: Churchill Livingstone 2003. 1105-1108.
  89. Clark HF, Offit PA. Vaccines for Rotavirus gastroenteritis. Universally needed for infants. Ped Ann 2004;33(8):537-543.
  90. Santos N, Hoshino Y. Global distribution of Rotavirus serotypes/genotypes and its implication for the development and implementation of an effective Rotavirus vaccine. Rev Med Virol 2005; 15:29-56.
  91. Rahmann M et al. Predominance of rotavirus G9 genotype in children hospitalized for rotavirus gastroenteritis in Belgium during 1999-2003 J Clin Virol 2005;33:1-6.
  92. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279-1295.
  93. Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital acquired diarrhea in children. Vaccine 2004;22:49-54.
  94. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279 1295.
  95. Clark HF, Offit PA. Vaccines for Rotavirus gastroenteritis. Universally needed for infants. Ped Ann 2004;33(8):537-543.
  96. Raebel MA, Ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy 1999;19(11):1279-1295.
  97. Clark HF, Offit PA. Vaccines for Rotavirus gastroenteritis. Universally needed for infants. Ped Ann 2004;33(8):537-543.
  98. WHO position paper www.who.int/vaccines-diseases/diseases/rotavirusdisease.shtml (viewed on 20.04.06).
  99. Moulin F et al. Hospitalization for acute community-acquired rotavirus gastroenteritis: a 4-year survey. Arch Pediatr 2002;9(3):255-261.
  100. Johansen K et al. Incidence and estimates of the disease burden of rotavirus in Sweden. Acta Paediatr 1999; 426(88):20-23.
  101. Parashar UD et al. Global illness and deaths caused by rotavirus disease in children. Emerg Inf Dis 2003;9:565-572.
  102. Verstraeten T., Wolleswinkel-van den Bosch JH, Burden of disease in the new European Union, ESPID 2005, 18-20 May, Valencia, Spain (abstract).
  103. Le Roux P et al. Nosocomial infections in a pediatric ward: epidemiology and quality research. Arch. Pediatr 2004;11:908-915.
  104. Moulin et al. Superposition des épidémies de rotavirus et de virus respiratoire syncytial à Paris de 1993 à 1998. Bull épidem hebdo 1999;24:1-8.
  105. http://www.grog.org/cgi-files/db.cgi?action=bulletin_vrs (viewed on 20.04.06).
  106. Lorgelly PK et al. Infantile gastroenteritis in the community: a cost of illness study. ISPOR, Washington, May 2005 (abstract).
  107. Melliez H et al., Morbidité et cout des infections à rotavirus en France. 23ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RCIAI), Paris, Décembre 2003 (abstract).
  108. Fontana et al. Costs associated with outpatient diarrhoea in infants and toddlers: a nationwide study of the Italian Society of Paediatric Gastroenterology and Hepatology. Dig Liver Dis. 2004; 36:523-527.
  109. European Union Invasive Bacterial Infections Surveillance (EU-IBIS), 1999-2001 reports.
  110. Institut de Veille Sanitaire. Base de données des infections invasives à méningocoques : Nombre et proportion des infections invasives à méningocoques par sérogroupe en France. 1998-2003. Available from : http://www.invs.sante.fr/surveillance/iim/web_meni.htm (viewed on 20.04.06).
  111. Atkinson et al. "Epidemiology and Prevention of vaccine preventable diseases" 8th Edition, January 2004;10:116-117;11:136-137;12:146- 147:161.
  112. ProQuad® SMPC.
  113. Individuals from 12 months of age should receive two dosesof ProQuad or a single dose of ProQuad followed by a second dose of a monovalent varicella vaccine to ensure optimal protection against varicella (ProQuad® SMPC).
  114. Knuf and al. Immunogenicity and SAfety of Two Doses of Tetravalent Measles-Mumps- Rubella-Varicella Vaccine in Healthy Children. The PEdiatric Infectious Disease Journal. Vol 25, Number 1, January 2006.
  115. Black S et al. Post Marketing evaluation of the safety and effectiveness of varicella Pediatr Infect Dis J 1999;18:1041-6.
  116. Bose A, Coen P, Tully J, Viner R, and Booy R. "Effectiveness of meningococcal C conjugate vaccine in teenagers in England." The Lancet 361, no. 9358 (2003): 675-676.
  117. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, and Ramsay ME. "Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction." The Lancet 364, no. 9431 (2004): 365-367.
  118. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, van Rie A, Bogaerts H and Storsaeter J. "Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine." Vaccine 21, no. 17/18 (2003): 2024-2030.
  119. Schmitt HJ, Vonkries R, Hassenpflug B et al. Hæmophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (inactivated Poliovirus) / H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001;20:767-74.